MONARCS

Monoclonal Anti-TNF: A Randomized Controlled Sepsis. A clinical trial, conducted in 157 US sites, which evaluated the efficacy of afelimomab in managing sepsis and septic shock, selecting the patients using Il-6, a cytokine marker for severity of inflammation
Results Treated patients had a 36% mortality; untreated patients, 33%

MONARCS

Immunology A clinical trial–Monoclonal Anti-TNF: a Randomized Controlled Sepsis trial which evaluated the efficacy of afelimomab in managing sepsis and septic shock, selecting the Pts using Il-6, a cytokine marker for severity of inflammation; treated Pts had a 36% mortality; untreated Pts, 33%. See Afelimomab, Sepsis.